Gabriela V Salamone1,2, Carolina C Jancic3,4, David A Rosso1, Micaela Rosato1, Juan Iturrizaga5, Nazareno González6, Carolina M Shiromizu1, Irene A Keitelman1, Juan V Coronel1, Fernando D Gómez7, María M Amaral7, Alejandra T Rabadan5. 1. Instituto de Medicina Experimental - CONICET - Academia Nacional de Medicina, Buenos Aires, Argentina. 2. Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. 3. Instituto de Medicina Experimental - CONICET - Academia Nacional de Medicina, Buenos Aires, Argentina. cjancic@fmed.uba.ar. 4. Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. cjancic@fmed.uba.ar. 5. División Neurocirugía, Instituto de Investigaciones Médicas A Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina. 6. Instituto de Investigaciones Biomédicas (INBIOMED) - Universidad de Buenos Aires - CONICET, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina. 7. Laboratorio de Fisiopatogenia, Departamento de Fisiología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.
Abstract
PURPOSE: γδ T lymphocytes are non-conventional T cells that participate in protective immunity and tumor surveillance. In healthy humans, the main subset of circulating γδ T cells express the TCRVγ9Vδ2. This subset responds to non-peptide prenyl-pyrophosphate antigens such as (E)-4-hydroxy-3-methyl-but-enyl pyrophosphate (HMBPP). This unique feature of Vγ9Vδ2 T cells makes them a candidate for anti-tumor immunotherapy. In this study, we investigated the response of HMBPP-activated Vγ9Vδ2 T lymphocytes to glioblastoma multiforme (GBM) cells. METHODS: Human purified γδ T cells were stimulated with HMBPP (1 µM) and incubated with GBM cells (U251, U373 and primary GBM cultures) or their conditioned medium. After overnight incubation, expression of CD69 and perforin was evaluated by flow cytometry and cytokines production by ELISA. As well, we performed a meta-analysis of transcriptomic data obtained from The Cancer Genome Atlas. RESULTS: HMBPP-stimulated γδ T cells cultured with GBM or its conditioned medium increased CD69, intracellular perforin, IFN-γ, and TNF-α production. A meta-analysis of transcriptomic data showed that GBM patients display better overall survival when mRNA TRGV9, the Vγ9 chain-encoding gene, was expressed in high levels. Moreover, its expression was higher in low-grade GBM compared to GBM. Interestingly, there was an association between γδ T cell infiltrates and TNF-α expression in the tumor microenvironment. CONCLUSION: GBM cells enhanced Th1-like profile differentiation in phosphoantigen-stimulated γδ T cells. Our results reinforce data that have demonstrated the implication of Vγ9Vδ2 T cells in the control of GBM, and this knowledge is fundamental to the development of immunotherapeutic protocols to treat GBM based on γδ T cells.
PURPOSE: γδ T lymphocytes are non-conventional T cells that participate in protective immunity and tumor surveillance. In healthy humans, the main subset of circulating γδ T cells express the TCRVγ9Vδ2. This subset responds to non-peptide prenyl-pyrophosphate antigens such as (E)-4-hydroxy-3-methyl-but-enyl pyrophosphate (HMBPP). This unique feature of Vγ9Vδ2 T cells makes them a candidate for anti-tumor immunotherapy. In this study, we investigated the response of HMBPP-activated Vγ9Vδ2 T lymphocytes to glioblastoma multiforme (GBM) cells. METHODS: Human purified γδ T cells were stimulated with HMBPP (1 µM) and incubated with GBM cells (U251, U373 and primary GBM cultures) or their conditioned medium. After overnight incubation, expression of CD69 and perforin was evaluated by flow cytometry and cytokines production by ELISA. As well, we performed a meta-analysis of transcriptomic data obtained from The Cancer Genome Atlas. RESULTS: HMBPP-stimulated γδ T cells cultured with GBM or its conditioned medium increased CD69, intracellular perforin, IFN-γ, and TNF-α production. A meta-analysis of transcriptomic data showed that GBM patients display better overall survival when mRNA TRGV9, the Vγ9 chain-encoding gene, was expressed in high levels. Moreover, its expression was higher in low-grade GBM compared to GBM. Interestingly, there was an association between γδ T cell infiltrates and TNF-α expression in the tumor microenvironment. CONCLUSION: GBM cells enhanced Th1-like profile differentiation in phosphoantigen-stimulated γδ T cells. Our results reinforce data that have demonstrated the implication of Vγ9Vδ2 T cells in the control of GBM, and this knowledge is fundamental to the development of immunotherapeutic protocols to treat GBM based on γδ T cells.
Authors: Chia-Hung Christine Hsiao; Xiaochen Lin; Rocky J Barney; Rebekah R Shippy; Jin Li; Olga Vinogradova; David F Wiemer; Andrew J Wiemer Journal: Chem Biol Date: 2014-07-24
Authors: Kia-Joo Puan; Chenggang Jin; Hong Wang; Ghanashyam Sarikonda; Amy M Raker; Hoi K Lee; Megan I Samuelson; Elisabeth Märker-Hermann; Ljiljana Pasa-Tolic; Edward Nieves; José-Luis Giner; Tomohisa Kuzuyama; Craig T Morita Journal: Int Immunol Date: 2007-04-19 Impact factor: 4.823
Authors: P Fisch; M Malkovsky; S Kovats; E Sturm; E Braakman; B S Klein; S D Voss; L W Morrissey; R DeMars; W J Welch Journal: Science Date: 1990-11-30 Impact factor: 47.728
Authors: Mohindar M Karunakaran; Carrie R Willcox; Mahboob Salim; Daniel Paletta; Alina S Fichtner; Angela Noll; Lisa Starick; Anna Nöhren; Charlotte R Begley; Katie A Berwick; Raphaël A G Chaleil; Vincent Pitard; Julie Déchanet-Merville; Paul A Bates; Brigitte Kimmel; Timothy J Knowles; Volker Kunzmann; Lutz Walter; Mark Jeeves; Fiyaz Mohammed; Benjamin E Willcox; Thomas Herrmann Journal: Immunity Date: 2020-03-09 Impact factor: 31.745